Baird analyst Tristan Gerra said Texas Instruments posted results that suggested stabilization in end-demand, however its seasonal Q1 guidance and lack of rebound in utilization rates suggests the company has yet to see a positive inflection point in end-demand. The analyst believes there may be better visibility after the Chinese New Year but that a seasonal Q2 rebound is already priced into the shares. Gerra maintained his Neutral rating and raised his price target to $130 from $105 on Texas Instruments shares.

Baird raised the firm's price target on Texas Instruments to $175 from $125 and keeps a Neutral rating on the shares. The firm said any unexpected/incremental softening in demand would likely trigger price cuts given the current environment of low lead times and excess capacity, and the shape of 2H recovery will be critical in addressing inventory levels.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

TD Cowen analyst Joshua Buchalter raised the firm's price target on Texas Instruments to $175 from $160 and keeps a Hold rating on the shares. The firm said the print wasn't great but an important improvement and positive indicator on stability for the group. That said, numbers still need to move meaningfully higher to build medium-term valuation support or material buyback growth.

BofA raised the firm's price target on Texas Instruments (TXN) to $190 from $175 and keeps a Neutral rating on the shares. TI's small Q1 beat and inline but sequentially rising Q2 sales guidance, "while modest, potentially marks a recovery inflection in industrial chip demand," with positive read-across for U.S. peers such as Analog Devices (ADI), Microchip (MCHP), NXP Semiconductors (NXPI) and On Semiconductor (ON), the analyst tells investors. However, despite an expected recovery, TI's sustained high capex intensity could keep reported calendar year 2024-26 pro-forma EPS below $6 per share, the analyst added.